TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway.

This is a pre print version of the following article:

Original Citation:
TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. / Neri F;Dettori D;Incarnato D;Krepelova A;Rapelli S;Maldotti M;Parlato C;Paliogiannis P;Oliviero S. - In: ONCOGENE. - ISSN 0950-9232. - 34(2015), pp. 4168-4176.

Availability:
This version is available http://hdl.handle.net/2318/150019 since 2016-08-12T10:55:30Z

Published version:
DOI:10.1038/onc.2014.356

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
This is an author version of the contribution published on:

Questa è la versione dell’autore dell’opera:


The definitive version is available at:

La versione definitiva è disponibile alla URL:

[http://www.nature.com/onc/journal/v34/n32/full/onc2014356a.html]
TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway

Francesco Neri ¹, Daniela Dettori ¹, Danny Incarnato ¹,², Anna Krepelova ¹,³, Stefania Rapelli ¹,³, Mara Maldotti ¹, Caterina Parlato ¹, Panagiotis Paliogiannis ⁴, and Salvatore Oliviero ¹,²*  

¹ Human Genetics Foundation (HuGeF), via Nizza 52, Torino, Italy.  
² Dipartimento di Scienze della Vita e Biologia dei Sistemi, Università di Torino, via Accademia Albertina, 13, Torino, Italy.  
³ Dipartimento di Biotecnologie Chimica e Farmacia, Università di Siena. via Fiorentina 1, Siena, Italy.  
⁴ Dipartimento di Scienze Chirurgiche, Microchirurgiche e Mediche, Viale S. Pietro 43, Università di Sassari, Sassari, Italy.  

* correspondence to:  
Salvatore Oliviero Email: salvatore.oliviero@hugef-torino.org
Abstract

Ten eleven translocation (TET) enzymes catalyse the oxidative reactions of 5-methylcytosine (5mC) to promote the demethylation process. The reaction intermediate 5-hydroxymethylcytosine (5hmC) has been shown to be abundant in embryonic stem cells and tissues, but strongly depleted in human cancers. Genetic mutations of TET2 gene were associated with leukaemia, whereas TET1 downregulation has been shown to promote malignancy in breast cancer. Here, we report that TET1 is downregulated in colon tumours from the initial stage. TET1 silencing in primary epithelial colon cells increase their cellular proliferation while its re-expression in colon cancer cells inhibits their proliferation and the growth of tumour xenografts even at later stages. We found that TET1 binds and maintains hypomethylated the promoter of the DKK genes inhibitors of the WNT signalling. Downregulation of TET1 during colon cancer initiation leads to repression, by DNA methylation, the promoters of the inhibitors of the WNT pathway resulting in a constitutive activation of the WNT pathway. Thus the DNA hydroxymethylation mediated by TET1 controlling the WNT signalling is a key player of tumour growth. These results provide new insights for understanding how tumours escape cellular controls.
Introduction

DNA methylation plays an essential role in the remodelling of the chromatin structure during development and tissue differentiation \(^1\)\(^-\)\(^5\). Deficient DNA methylation establishment, due to mutation in DNA methyltransferases Dnmt3a or Dnmt3b, can lead to genetic diseases, such as ICF syndrome, and differentiation-associated methylation patterns are found altered in the majority of human cancers \(^6\)\(^-\)\(^10\). Irregular DNA methylation patterns are often associated with the tumour cells, where a general hypomethylation takes place together with hypermethylation of specific regions \(^7\)\(^,\)\(^9\)\(^,\)\(^11\)\(^-\)\(^13\). Colon cancer is one of the most susceptible diseases to the deregulation of DNA methylation and often the tumour initiation is due to genetic mutation accomplished by epigenetic inactivation of the WNT pathway inhibitors \(^10\)\(^,\)\(^14\)\(^-\)\(^16\).

5-hydroxymethylcytosine (5hmC) is a recently discovered epigenetic modification catalysed by the Ten eleven translocation (TET) proteins that mediate the sequential oxidation of 5-methylcytosine (5mC) to 5hmC, leading to eventual DNA demethylation \(^17\)\(^-\)\(^21\). 5hmC is lost in human cancers, but the functional significance of this event is not still understood \(^22\)\(^-\)\(^25\). Several mechanisms can lead to loss of 5hmC in cancers, including mutations in IDH or TET2 genes \(^26\)\(^-\)\(^29\). Reduced levels of 5hmC, associated with mutations or reduced expression of TET genes, have been implicated in myeloproliferative disorders \(^22\)\(^-\)\(^25\)\(^,\)\(^29\)\(^-\)\(^34\). Downregulation of TET1 has been shown to promote cancer invasion and metastasis \(^35\)\(^,\)\(^36\). Here we show that TET1 downregulation is not only linked to tumour progression and malignancy, but it is necessary for tumour initiation and growth. We reveal the molecular function of TET1 protein in cancer development and clarify the mechanism by which the WNT pathway inhibitors are epigenetically switched off during cellular transformation. This mechanism provides the explanation for specific promoter hypermethylations in cancer, which are TET-dependent, whereas a general hypomethylated state could
be caused by deregulation of the DNA methyltransferase machinery.

Results

**TET1 downregulation is an early event in cell transformation**

We analysed the level TET1 and hydroxymethylation in colon tumours. We found that TET1 and 5hmC are strongly reduced in primary colon cancers with respect to the surrounding healthy tissue (Figure 1a and b). Interestingly, in our samples TET1 was downmodulated independently from the tumour stage and the histopathological grade (Supplementary Figure S1a). To understand how TET1 is regulated in tumours with respect in tumour initiation and progression, we analysed a metadataset from stages I to IV of colon, breast, lung, and rectum primary tumours. Analysis of the genes differentially expressed in this cohort of 887 adenocarcinomas revealed that TET1, but not TET2 or TET3, was strongly downregulated in tumours since stage I (Supplementary Figure S1b). These data demonstrate that TET1 downregulation is an early event in tumourigenesis. Quantitative RT-PCR (RT-qPCR) analysis showed TET1 expression in human colon tissues and in normal epithelial colon cells (CCD), which were positive for the 5hmC modification, while TET1 and 5hmC modification were almost undetectable in all the analysed colon cancer cell lines (Figure 1c and d). To understand TET1 functional role in colon cells we silenced TET1 in the normal CCD cells using two different short hairpin RNAs (shRNAs) (Figure S2a). TET1-knockdown CCD cells showed an increase in cell proliferation (Figure S2b) suggesting that TET1 plays a role in the control of cell growth. To perform a rescue experiment we silenced TET1 using the two shRNA together to increase the knockdown efficiency and re-expressed TET1 by using a
cDNA missing its 3’ UTR. TET1 re-expression in TET-silenced cell induced a full recovery of the level of 5hmC as well as a reduction of the cell proliferation rate (Figure 1e-g).

**TET1 blocks colon cancer cell growth in vitro and in vivo**

The above results show that *TET1* is downregulated in colon cancers and that its downregulation in normal cells promotes cell proliferation. Next, we analysed the effects of *TET1* re-expression on the growth of colon cancer cells. To this end we first generated Caco-2 and SW48 human colorectal carcinoma cell lines stably expressing *TET1* under the control of a doxycycline-inducible (Dox) promoter (Figure 2a). *TET1* expression did not alter TET2 or TET3 expression (Supplementary Figure S3a and b). Upon cell treatment with Dox, TET1 induced an increased level of 5hmC and strongly reduced the growth rate of both cell lines (Figure 2b and c). These effects were due to the enzymatic activity of TET1, which lengthens the G0/G1 phase of the cell cycle while the hydroxylase deficient mutant TET1-H1672Y/D1674A (TET1-mut) was not able to interfere with cell growth *in vitro* (Supplementary Figure S3 c-f). Since both Caco-2 and SW48 form spheres under serum-free conditions (Supplementary Figure S4a and b) we also tested the effect of *TET1*-dependent hydroxymethylation on tumour initiating cells. *TET1* induction caused a significant reduction of sphere formation (Figure 2d). We analysed the surface markers CD166, CD44, and EpCAM that increase during sphere growth but we did not observe any changes of these markers in Caco-2 or SW48 cells after TET1 re-expression suggesting that TET1 decreases cell proliferation independently from the cell fraction source and that it does not favor the proliferation of any particular fraction (Figure S4c).

To evaluate whether *TET1* plays a role in tumour growth *in vivo* we injected the
Caco-2 and SW48 cell lines in nude mice. A group of animals were then treated with Dox to induce the expression of TET1 (Figure 3a). The size and weight of xenografts expressing TET1 were dramatically smaller than the control group in which TET1 was not induced (Figure 3b, c, and d, and Supplementary Figure S5a). TET1 expression blocked the growth of the tumours derived from both cell lines from the beginning (Figure 3b). Remarkably, growth arrest was obtained not only when TET1 was induced early after tumour cells inoculation but also when TET1 was induced when the tumours were already established several days later (Figure 3e and Supplementary Figure S5b). These results are consistent with the strong inhibition of cell growth observed in vitro.

**TET1 inhibits WNT signalling pathway**

To understand the molecular function of TET1 expression on colon cancer, we performed a genome-wide RNA-Seq analysis of the mRNA of Caco-2 cells treated for 96h with doxycycline. This analysis revealed that TET1 alters the expression of about 300 genes of which more than 60% were upregulated (Figure 4a). Interestingly, analysis of the genome-wide methylation pattern of wild type Caco2 cells showed that the genes upregulated by TET1 where those that exhibited a significant higher methylation level on their promoters (Figure 4b). Gene ontology analysis showed a significantly enrichment in the WNT/β-catenin signalling pathway (p-value < 0.001) of the TET1-deregulated genes and many of them are involved directly or indirectly to the canonical WNT pathway (Figure 4c and d). We measured the level of nuclear β-catenin (CTNNB1) and we observed its reduced nuclear localization after TET1 re-expression in both cancer cell lines (Figure 4e and f). We then analysed the effect of TET1 expression on the WNT/β-catenin signalling pathway by using the TCF/LEF-dependent luciferase reporter assay since these cancer cells show high activity of this pathway (Supplementary Figure S6a).
induced a downregulation of WNT/β-catenin signalling in both cell lines (Figure 4g). Also in this case, the enzymatic activity of TET1 was required to downmodulate the WNT pathway activity (Supplementary Figure S6b). To demonstrate that the decreased proliferation rate was due to the TET1-dependent inactivation of the WNT pathway, we expressed a stable nuclear β-catenin in the Caco-2 and SW48 lines treated with Dox (Figure 4h). The expression of β-catenin in these cells rescued the luciferase activity and the cell growth (Figure 4i and Supplementary Figure S6c) demonstrating that the TET1-induced block of cell proliferation acts via WNT pathway inhibition. Interestingly, immunofluorescence analysis and Western blot of nuclear extracts of 24 days old xenografts showed sustained β-catenin nuclear localization in untreated but not in Dox treated mice (Figure S6d and e) indicating that also in vivo occurs a reduced WNT pathway activity in TET1 expressing tumours.

**TET1-dependent demethylation promotes transcriptional activation of the WNT pathway inhibitors**

RNA-Seq analysis showed proliferation-associated genes dowregulated in TET1 expressing Caco-2 cells, such as MYC and Cyclin D2 (CCND2) that are downstream targets of the WNT pathway. Importantly, DKK and SFRP genes, that are upstream inhibitors of the WNT pathway, were found upregulated in TET1 expressing cells (Figure 5a). RT-qPCR analysis at 96 hours after Dox treatment showed the upregulation of DKK3 and DKK4 and the downregulation of MYC and Cyclin D2 in both the cell lines (Figure 5b). Chromatin Immunoprecipitation (ChIP) analysis showed the binding of TET1 on the promoters of DKK genes (Figure 5c). Analysis of the level of 5hmC and 5mC revealed a significant increase of 5hmC on the DKK3 and DKK4 genes associated with a reduction of 5mC signal (Figure 5d
and e). Interestingly, DKK1 and DKK2 expression was not affected by TET1 (Figure 5b). DKK1 was not methylated suggesting that on this gene the transcriptional repression is not mediated by DNA methylation. DKK2 showed an elevated level of DNA methylation, which was not significantly reduced by TET1 expression at 96 hours after Dox treatment (Figure 5e). To demonstrate that TET1 functions via repressing of the WNT inhibitors we performed a rescue experiment in which we silenced the DKK3 and DKK4 genes and re-expressed TET1 in Caco-2 and SW48 cells (Figure 5f). We used two different shRNAs to perform the knockdown of each DKK gene. The knockdown of both DKK3 and DKK4 restored the cell growth inhibition by TET1 expression (Figure 5g). Interestingly, RT-qPCR analysis of Caco-2 and SW48 tumour xenografts at later time points showed DKK3 and DKK4 upregulation as well as MYC and Cyclin D2 downregulation (Figure S7). It is worth noting that the tumours expressed also DKK2 (Figure S7), which was not upregulated within 96 hours of TET1 expression (Figure 5b) suggesting a cumulative TET1-dependent demethylation on the DKK2 promoter in xenografts.

Taken together the above data demonstrate that TET1 inhibits cancer cells growth by repressing the WNT pathway, via demethylation of the promoters of the WNT inhibitors DKK3 and DKK4.

**Discussion**

We here demonstrate that TET1 loss in colon cancer is an early event that favours cell proliferation. We propose a model by which TET1 downmodulation contributes to tumour initiation. Indeed, our data show that TET1 silencing in normal epithelial colon cells facilitates cell cycle progression and that its re-expression in transformed
colon cells blocks cell growth. Accordingly, meta-analysis on a cohort of 887 adenocarcinomas showed that TET1 mRNA is downregulated from the first stage of tumours, especially in colon-rectal cancers. Thus the downmodulation of TET1 takes place already at their initial stage suggesting that, in order to grow, cancer cells must downregulate TET1 expression.

Our work demonstrated that TET1 downmodulation is required for cancer cell growth as its re-expression in cancer cells inhibits their growth both in vitro and in vivo. We found that TET1 oncosuppressor function is mediated by its enzymatic activity, since the catalytically dead mutant was unable to block cancer cell growth.

The significant increase of 5hmC in TET1 expressing cells suggests that this modification could play gene regulatory functions in addition of being an intermediate for C-demethylation. It has been previously shown in breast tissue that TET1 is required to maintain the expression of the antimetastatic miR200 and TIMP genes by inhibiting the methylation on their promoters and its downregulation in breast cancer results in the lower expression of these genes. In contrast, in colon cancers, we could not find expression of miR200 or the downregulation of TIMP genes (data not shown). Instead, we found that TET1 targeting the DKK and SFRP genes induced a reduction of the 5mC and an increase of the 5hmC marks on their promoter regions leading to the expression of these genes.

Thus, in colon tumours the downregulation of the inhibitors of the WNT pathway, DKKs and SFRPs, due to TET1 downmodulation, results in the increased of tumour growth. This implies that in different tissues, due to the cell-specific epigenetic landscape, cells respond with different phenotypic outputs to TET1 downmodulation. WNT pathway inhibitors DKKs and SFRPs are epigenetically inactivated by DNA methylation in colorectal cancer cells and this event is able to sustain tumour development. Repression of these inhibitor genes allows a constitutive WNT signalling that sustains the proliferation of cancer cells. Our data demonstrate that
the gain of DNA methylation on these promoters is due to the reduced TET1-dependent demethylation activity.

In colon cancer cells, the loss of TET1 promotes DNA methylation of these promoters leading to a full repression of the genes, which is revertible by TET1 re-expression.

In summary, our data show that TET1 acts as an oncosuppressor because it plays a central role in the epigenetic control of colon cancer growth. TET1 reactivation, although challenging, can represent a novel therapeutic approach in cancer.
Material and methods

Cell culture, transfection and transduction

Caco2 and SW48 cells were cultured in RPMI medium with 10% FCS. For Doxycycline-inducible stable clone generation Caco2 and SW48 cells were transduced with 10 µl of concentrated virus of pLVX-Tight-Puro-TET1 and pLVX-Tet-On-Advanced Vectors and selected for 7 days in Puromycin 1 mg/ml and Hygromycin B 100 mg/ml. For induction of TET1, Doxycycline was used at 1 mg/ml. Transfections were performed using Lipofectamine 2000 Transfection Reagent (Invitrogen) according to the manufacturer's protocol. CCD normal colon epithelial cells were acquired from ATCC (CCD 841 CoN (ATCC® CRL-1790™)) and cultured as described by ATCC. For shRNA transduction, 10 µl of concentrated virus of PLKO vectors were incubated with cells for 16 hours.

Animals

C57BL/6 mice (8-10 weeks old) were obtained from our mouse facility. BALB/c-nude (6 weeks old) were obtained from Janvier-labs. Housing and all experimental animal procedures were approved by the Institutional Animal Care and Research Advisory Committee of the University of Turin.

Constructs

pAAV-EF1a-HA-hTet1CD-WPRE-PolyA and pAAV-EF1a-HA-hTet1CDmu-WPRE-PolyA were purchased from Addgene (plasmid 39454 and 39455). pLVX-Tight-Puro Vector and pLVX-Tet-On-Advanced Vector were purchased from Clontech (plasmid...
S4934 and S4932). Catalytic domain of TET1 was sub-cloned into pLVX-Tight-Puro-Vector. TET1, DKK3 and DKK4 shRNAs were constructed using the TRC hairpin design tool (http://www.broadinstitute.org/rnai/public/seq/search) choosing the following hairpin sequences:

ACACAAACTTGCTTCGATAATT (TET1, shRNA1)
TTGTGCCTCTGGAGTTATAA (TET1, shRNA2).
GACACGAAGGTTGGAAATAAT (DKK3, shRNA1)
GGCATGCACATCTGGAATTAA (DKK3, shRNA2).
TCGGCAGCATGCTCGATTAAG (DKK4, shRNA1)
GGAAGCCAAGTATTAAGAAAT (DKK4, shRNA2).

Annealed oligonucleotides were cloned into pLKO.1 vector (Addgene: 10878) and each construct was verified by sequencing. Super8X-TOPFlash, negative control Super8X-FOPFlash and pCS2-CTNNB1-S33A-myc-tag were kindly provided by Professor Valeria Poli.

**Antibodies**

The antibodies were purchased from Millipore (anti-TET1), Abcam (anti-ssDNA), Cell Signalling (anti-CD44-8E2, anti-EpCAM), Sigma-Aldrich (anti-B-actin), Epitomics (anti-CD166), BD Transduction Laboratory (anti-CTNNB1), SantaCruz (anti-LaminA-sc20680), and Active Motif (anti-5mC, anti-5hmC).

**DNA Extraction and dot-blot analysis**

Genomic DNA was extracted from cells using DNeasy Blood and Tissue kit (Qiagen). For dot-blot analysis, extracted genomic DNA was sonicated for 15 cycles
to obtain 300 bp fragments, denatured with 0.4 M NaOH and incubated for 10 min a 95°C prior to being spotted onto HybondTM-N+ (GE Healthcare). Membrane were saturated with milk 5% and incubated 16h with the specific antibodies.

**RNA extraction and RT-PCR analysis**

RNA extraction and RT-PCR were performed as in 42. Briefly, total RNA was extracted using TRIzol reagent (Invitrogen). Real-time PCR was performed using the SuperScript III Platinum One-Step Quantitative RT-PCR System (Invitrogen, cat.11732-020) following the manufacturer’s instructions. Primers sequences are provided in Supplementary Table S1.

**RNA sequencing**

For mRNA-Seq, libraries were generated from total RNA using TruSeq RNA Sample Preparation v2 in according to the manufacturer’s protocol. Samples were sequenced on Illumina HiScanSQ platform. Reads were mapped on hg19 using TopHat v2.0.6 43 and mRNA quantification was performed using Cuffdiff v2.0.2 44. Up- and down-regulated genes are provided in Supplementary Table S3. Raw data are deposited under the GEO accession GSE53172.

**ChIP and (h)MeDIP**

ChIP were performed as in 45. For MeDIP and hMeDIP, 2 µg of sonicated DNA was denatured at 95°C for 10 minutes, immediately cooled on ice for 10 minutes and diluted in 400 µl of IP buffer (10 mM Na-Phosphate pH 7.0 140 mM NaCl 0.05 %
Triton X-100) with 10 µl of anti-5mC or anti-5hmC. After incubation of 2 hours with at 4°C with overhead shaking, 30 µl of saturated Dynabeads anti-mouse IgG were added and incubate for other 2 hours. After five washes with IP buffer, DNA was eluted with Proteinase K for 2 hours and purified using the QIAQuick PCR Purification Kit (QIAGEN) according to the manufacturer’s instructions. DNA was DNA was analyzed by quantitative real-time PCR by using a SYBR GreenER kit (Invitrogen). Primers sequences are provided in Supplementary Table S2.

**Protein extraction and Western blotting**

Extracts were performed as previously described. Briefly, cells were resuspended in F-buffer (10mM TRIS-HCl pH 7.0, 50mM NaCl, 30mM Na-pyrophosphate, 50mM NaF, anti-proteases) and sonicated for 3 pulses to obtain total cell extracts. Nuclear protein extraction was performed as in. Extracts were quantified using bicinchoninic acid (BCA) assay (BCA protein assay kit; catalog no. 23225; Pierce) and were run in SDS-polyacrylamide gels at different percentages, transferred to nitrocellulose membranes and incubated 16 hours with specific primary antibodies.

**Luciferase assay**

Cells were transfected with the indicated Firefly luciferase reporter constructs with 1/10 of Renilla Luciferase reporter construct. After 24 h cells were analyzed for luciferase and Renilla activity using a Dual-Glo luciferase assay (Promega). Promoter activity values were normalized using Renilla activity.

**Immunofluorescence**
For immunostaining tumours were dissected and fixed in 2% PAF overnight at 4°C, dehydrated and embedded in paraffin. Thick sections (5 µm thickness) were then incubated with anti-CTNNB1 antibody.

**Cell growth and cell cycle analysis**

For cell growth assay, 5x10⁴ cells were plated in 35mm wells and counted at the indicated time point using Scepter™ Automated Cell Counter (Millipore). For FACS cell cycle analysis, the cells were stained with propidium iodide (PI) solution (0.1% Triton, 200 mg/ml RNase, 20 mg/ml PI in PBS) for 30 min at room temperature. Acquisition was performed using Becton Dickinson FACS Canto and analysis was done with FACS FlowJo Software.

**FACS analysis**

FACS analysis was performed as previously described (Neri et al., 2012) Briefly, cells were first incubated with primary antibodies for 30 minutes in PBS-1% bovine serum albumin (BSA) and after 3 washes were stained with conjugated secondary antibodies.

**Colonsphere assay**

Colonsphere assay was performed as in ³⁷ with the following modifications: cells were plated as single cell in 96 well round bottom in DMEM/F12 medium supplemented with BSA 0.4%, Heparin 4mg/ml, Insulin 20mg/ml, B27, N2, bFGF 10ng/ml, EGF 20ng/ml and cultured for 10 days before analysis.
Mouse and tumours injection

Caco2 and SW48 human colon tumour cell lines were harvested and single-cell suspensions of $1 \times 10^6$ in 100 ul of PBS were injected subcutaneously into the right flank of mice. Tumour volumes were measured every two days with a caliber using the formula: $V = \pi \times [d^2 \times D] / 6$, where $d$ is the minor tumour axis and $D$ is the major tumour axis. The mice were sacrificed at defined time intervals after cell inoculation or when tumours reached a maximum size of 2 cm$^3$.

Bioinformatics analysis

Gene expression analysis of TET1, TET2 and TET3 was performed using The Cancer Genome Atlas TCGA database (http://cancergenome.nih.gov/) subdividing the cancers for their reported tumour stage where it was available, otherwise the data were not used. Gene ontology was performed using DAVID software $^{47,48}$

Conflict of interest

All the other authors declare no conflict of interest.

Acknowledgement

This work was supported by the Associazione Italiana Ricerca sul Cancro (AIRC) IG 2011/11982. We thank Carola Ponzetto and Riccardo Taulli for the critical reading of
References


48. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and

**Figure legends**

**Figure 1.**
Correlation between *TET1*/5hmC and (cancer) cell proliferation. (a) qRT-PCR of *TET1* mRNA in colon tumours samples and their relative healthy tissues. Error bars represent the standard deviation of 3 technical replicates. (b) Dot-blot analysis of 5hmC and 5mC in colon tumours samples and their relative healthy tissues. ssDNA was used as loading control. (c) qRT-PCR of *TET1* mRNA in the indicated cancer lines or primary cells. (d) Dot-blot analysis of 5hmC and 5mC in the indicated cancer lines or primary cells. ssDNA was used as loading control. (e) qRT-PCR of *TET1* mRNA in CCD normal human colon cells treated with a control shRNA, with two different shRNA against *TET1* or with two different shRNA against *TET1* plus TET1 cDNA. (f) Dot-blot analysis of 5hmC and 5mC in CCD cells treated as in (e). ssDNA was used as loading control. (g) Cell growth assay in in CCD cells treated as in (e). Error bars represent the standard deviation of 3 independent experiments.

**Figure 2.**
*TET1* regulates cancer cell proliferation. (a) Western Blot (WB) analysis of *TET1* in control or Doxycycline (Dox) treated Caco2 or SW48 colon cancer cell lines expressing inducible *TET1*. *ACTB* was used as loading control. (b-c) Dot-blot analysis of 5hmC and cell growth assay of wt or *TET1* inducible expressing (± Dox) Caco2 and SW48 cell lines. (d) Quantification of colonspheres obtained in colonspheres assay using the cell lines treated as in (c). Error bars represent the standard deviation of 3 independent experiments. (* pvalue < 0.01)
Figure 3.
*TET1* inhibits cancer growth. (a) qRT-PCR of *TET1* mRNA in the indicated cell line xenografts after 3 weeks. (b) Mouse tumour growth of TET1 inducible expressing (± Dox) Caco2 and SW48 cell line respectively. (c) Macroscopic view showing tumours upon resection from BALB/c-nude mice respectively of Caco2 and SW48 cell line implanted subcutaneously. (d) Tumours weight upon resection. (e) Reduced tumour growth of Caco2 and SW48 cell line by TET1 expression upon post-implantation Doxycycline (Dox) treatment from the indicated day. Error bars in the Fig. represent the standard deviation of at least 3 independent experiments.

Figure 4.
*TET1* negatively regulates Wnt pathway in cancer cells. (a) Up- and down-regulated genes obtained from RNA-Seq analysis in Caco2 cell line expressing *TET1* for 96h. (b) Promoter methylation percentage of the up- and down- regulated gene in Caco2 after 96h. Promoter methylation was calculated using RRBS data from Encode (GSM980582) as the percentage of methylated CpGs in the region between -1000/+500 from TSS. (c) Gene Ontology (GO) analysis of deregulated genes in Caco2 cell line expressing *TET1* after 96h. (d) Schematic representation of the canonical WNT pathway with in red the up-regulated genes and in blue the down-regulated genes by *TET1* expression in Caco2 cell line. (e) WB analysis of CTNNB1 in nuclear (Nuc) or cytoplasmatic (Cyt) extracts of Caco2 or SW48 cells treated with Dox at the indicated times. LAMIN A and ACTIN was used as loading control. (f) Nuclear localization loss of CTNNB1 in Doxycycline treated or untreated CACO-2 and SW48 cells for 48hours. DAPI is used for nuclei staining. (g) Caco2 and SW48 cells were transfected with a WNT-reporter (firefly TOP vector) and a Renilla luciferase (normalizing transfection control) constructs. The reporter activity was measured 24h after transfection in cells treated or not with Dox for 24h or 96h. (h) WB analysis of CTNNB1 in total extracts of Caco2 or SW48 cells treated with Dox and transfected with Mock or CTNNB1 (active form S33A). ACTB was used as loading control. i) Cell growth assay
in Mock or CTNNB1 transfected Caco2 and SW48 cells treated with Dox for TET1 induction. Error bars in the Figure represent the standard deviation of 3 independent experiments.

Figure 5.
TET1 derepresses WNT inhibitors. (a) Heatmap of the most regulated genes of the WNT pathway. (b) qRT-PCR of DKKs, MYC and CCND2 mRNA levels in Caco2 and SW48 cell lines ± Dox treatment. (c) ChIP analysis of the DKK gene promoters in Caco-2 and SW48 cells ± Dox treatment. (d-e) (h)MeDIP analysis of DKK gene promoters in Caco-2 and SW48 cells ± Dox treatment. (f) RT-qPCR of DKK3 and DKK4 in Caco2 and SW48 treated with Dox and transfected with control or DKK3 and DKK4 shRNAs. (g) Cell growth assay in Caco2 and SW48 cells treated as in (f). Error bars represent the standard deviation of 3 independent experiments. (* p-value < 0.01, ** p-value < 0.05).
Figure 1

(a) TET1 mRNA

(b) Chromatin modifications in colorectal cancer tissues and cell lines

(c) TET1 mRNA expression levels

(d) 5hmC, 5mC, ssDNA levels in colorectal cancer cell lines

(e) Fold change in TET1 expression

(f) 5hmC, 5mC, ssDNA levels in shTET1 and shTET1 + TET1

(g) Cell growth curve for CCD cells

Patient #:

HT29  Colo205  SW48  Caco2  HCT116

Figure 1
Figure 2
Figure 3

a) TET1 expression

b) Caco-2

SW48

Caco-2 SW48

- Dox + Dox - Dox + Dox

c) Caco-2

SW48

- Dox + Dox - Dox + Dox

d) Caco-2 (day 28)

SW48 (day 24)

e) Caco-2

SW48

- Dox + Dox (at 15 day)

- Dox + Dox (at 10 day)
Caco-2 + Dox

<table>
<thead>
<tr>
<th>GO analysis</th>
<th>category</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wnt signaling pathway</td>
<td>KEGG Pathway</td>
<td>7.33E-05</td>
</tr>
<tr>
<td>PPAR signaling pathway</td>
<td>KEGG Pathway</td>
<td>9.36E-03</td>
</tr>
<tr>
<td>signal transduction</td>
<td>Biological process</td>
<td>1.73E-09</td>
</tr>
<tr>
<td>extracellular matrix</td>
<td>Biological process</td>
<td>2.66E-04</td>
</tr>
<tr>
<td>cell cycle</td>
<td>Biological process</td>
<td>3.54E-02</td>
</tr>
</tbody>
</table>

**Figure 4**

- **a**: Caco-2 + Dox
- **b**: Box plot showing UP and DOWN
- **c**: GO analysis category p-values
- **d**: WNT Pathway diagram
- **e**: Western blot images (Dox: 0, 24, 96)
- **f**: Immunofluorescence images (Caco-2, SW48)
- **g**: TCF/LEF luciferase (Caco-2, SW48)
- **h**: Western blot images (Mock, CTNNB1)
- **i**: Graphs showing cell growth (Caco-2 + Dox, SW48 + Dox)
Figure 5

a) Most affected genes
WNT pathway

DKK4
DKK3
SFRP5
SFRP4
SOX2
TCF1
AXIN1
AXIN2
ID3
WNT8B
MET
PPARA
MYC
PPARG
CCND2

DOX: - +

b) Caco-2

Caco-2

SW48

TET1 ChIP

hMeDIP

MeDIP

Caco-2

SW48

Caco-2

SW48

Caco-2

SW48

Caco-2

SW48

f) Fold difference

Caco-2

SW48

g) Log2 fold change

Caco-2

SW48

Figure 5